NasdaqCM:LQDAPharmaceuticals
Liquidia (LQDA) Is Down 5.5% After YUTREPIA’s Launch Outpaces Expectations Amid Ongoing Patent Fight
In early 2026, Laughing Water Capital’s Q1 investor letter highlighted that Liquidia’s inhaled treprostinil therapy YUTREPIA has been launching with sales that continue to exceed expectations, while patent litigation with United Therapeutics over its use in PH-ILD remains unresolved.
The letter underscored that legal experts now see a favorable outcome as increasingly likely and suggested that strong YUTREPIA adoption, combined with a positive ruling, could support an annualized revenue run...